166 related articles for article (PubMed ID: 32351894)
1. Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases.
Ying X; Liu H; Wang M; Peng M; Ruan P; Verma V; Han G
Front Oncol; 2020; 10():517. PubMed ID: 32351894
[No Abstract] [Full Text] [Related]
2. Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC.
Ren Y; Wang SB; Zhou L; Liu SQ; Du LY; Li T; Jiang MQ; Lei KJ; Tan BX; Jia YM
Technol Cancer Res Treat; 2021; 20():15330338211011968. PubMed ID: 33955301
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apatinib combined with whole-brain radiation therapy with a simultaneous integrated boost for brain metastases from non-small cell lung cancer: a multicenter retrospective study.
Ma J; Bi J; Tuo X; Pi G; Li Y; Li Y; Zeng F; Gong H; Hu D; Han G
J Thorac Dis; 2022 Feb; 14(2):455-463. PubMed ID: 35280489
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
Ma J; Pi G; Bi J; Li Y; He H; Li Y; Hu D; Verma V; Han G
Clin Lung Cancer; 2021 Mar; 22(2):e211-e214. PubMed ID: 33187916
[TBL] [Abstract][Full Text] [Related]
5. Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma.
Fang SC; Zhang HT; Zhang YM; Xie WP
Onco Targets Ther; 2017; 10():447-452. PubMed ID: 28176910
[TBL] [Abstract][Full Text] [Related]
6. Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature.
Li L
Heliyon; 2022 Sep; 8(9):e10407. PubMed ID: 36119883
[TBL] [Abstract][Full Text] [Related]
7. Significant efficacy and well safety of apatinib combined with radiotherapy in NSCLC: Case report.
Zhao C; Zhang Q; Qiao W
Medicine (Baltimore); 2017 Dec; 96(50):e9276. PubMed ID: 29390380
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
Wu F; Zhang S; Gao G; Zhao J; Ren S; Zhou C
Cancer Biol Ther; 2018 Mar; 19(3):141-144. PubMed ID: 29261000
[TBL] [Abstract][Full Text] [Related]
9. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
10. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer.
Robin TP; Camidge DR; Stuhr K; Nath SK; Breeze RE; Pacheco JM; Liu AK; Gaspar LE; Purcell WT; Doebele RC; Kavanagh BD; Rusthoven CG
J Thorac Oncol; 2018 May; 13(5):715-720. PubMed ID: 29269007
[TBL] [Abstract][Full Text] [Related]
11. Whole-Brain Radiotherapy Combined With Anlotinib for Multiple Brain Metastases From Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study.
Liu J; Xu J; Ye W; Zhong W; Zhang X; Mao J; Wu D
Clin Med Insights Oncol; 2022; 16():11795549221079185. PubMed ID: 35250325
[TBL] [Abstract][Full Text] [Related]
12. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
13. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report.
Li T; Wang SB; Lei KJ; Jiang MQ; Jia YM
Medicine (Baltimore); 2019 Jan; 98(4):e14182. PubMed ID: 30681587
[TBL] [Abstract][Full Text] [Related]
14. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
15. Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review.
Yang D; Dai R; Zhang Q; Fang P
Saudi J Biol Sci; 2018 Jul; 25(5):888-894. PubMed ID: 30108437
[TBL] [Abstract][Full Text] [Related]
16. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma.
Zeng DX; Wang CG; Lei W; Huang JA; Jiang JH
Oncotarget; 2017 Sep; 8(39):66248-66253. PubMed ID: 29029508
[TBL] [Abstract][Full Text] [Related]
18. Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma.
Li X; Li X; Fang X; Yuan Y
Onco Targets Ther; 2018; 11():4047-4050. PubMed ID: 30038504
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy effects on brain/bone metastatic adenocarcinoma lung cancer and the importance of EGFR mutation test.
Qu BL; Cai BN; Yu W; Liu F; Huang YR; Ju ZJ; Wang XS; Ou GM; Feng LC
Neoplasma; 2016; 63(1):158-62. PubMed ID: 26639246
[TBL] [Abstract][Full Text] [Related]
20. A case report of apatinib in treating osteosarcoma with pulmonary metastases.
Zhou Y; Zhang W; Tang F; Luo Y; Min L; Zhang W; Shi R; Duan H; Tu C
Medicine (Baltimore); 2017 Apr; 96(15):e6578. PubMed ID: 28403086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
